Roche´s Cellavista System Successfully Used to Study the Self-Renewal Process of Embryonic Stem Cells

PENZBERG, Germany--(BUSINESS WIRE)-- A recent study (1) depicted the use of Roche´s Cellavista System to rapidly and effectively carry out a clonal analysis of embryonic stem (mES) colony self-renewal in an end-point assay. The Cellavista System proved to be useful for automated mES colony imaging, as well as characterization of colonies as differentiated and undifferentiated based on gating of morphological and intensity criteria. Little or no interference from the feeder cell layers was seen in the analysis of the images.

Embryonic stem cells are pluripotent cells that can differentiate into almost any specialized cell type and also have the ability to generate new, undifferentiated stem cells. The latter process is called self-renewal. Laboratories throughout the world routinely monitor embryonic stem cell colonies for signs of differentiation or self-renewal as a standard procedure for determining the effects of various factors on the self-renewal of mES cells. Generally, cultures are scored manually using a microscope to determine the number of differentiating and non-differentiating colonies. However, manual scoring of individual colonies is known to be a tedious process subject to inter-individual and intra-individual variation. In addition, due to the time-intensive nature of manual colony evaluation, experimental throughput is limited. As shown in the study, the Cellavista System offers an automated way to overcome theses limitations and enables its user to check the differentiation status rapidly and consistently.

More information please find at www.roche-applied-science.com.

(1) V. Vincent, D. ten Berge, Application Note “Clonal Analysis of mouse ES cells self-renewal”

About Roche

Headquartered in Basel, Switzerland, Roche (SWX:RO) (SWX:ROG) (Pink Sheets: RHHBY) is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80’000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

For life science research only. Not for use in diagnostic procedures.

CELLAVISTA is a trademark of Roche.

Other brands or product names are trademarks of their respective holders.



CONTACT:

Roche Diagnostics
Dr. Burkhard Ziebolz
Phone: +49 8856 604830
Email: [email protected]

KEYWORDS:   Europe  Germany

INDUSTRY KEYWORDS:   Stem Cells  Health  Biotechnology  Medical Devices  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.